Litcius/Paper detail

Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis

Kun Liu, Youwen Zhu, Yangying Zhou, Hong Zhu

2023Advances in Therapy13 citationsDOI

Topics & Concepts

MedicineCervical cancerInternal medicineRheumatologyOncologyPhysical therapyFamily medicineCancerEndometrial and Cervical Cancer TreatmentsHealth Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer
Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis | Litcius